Endoscopy 2020; 52(S 01): S145
DOI: 10.1055/s-0040-1704448
ESGE Days 2020 ePoster Podium presentations
Thursday, April 23, 2020 11:30 – 12:00 Endoscopic sleeve gastroplasty ePoster Podium 1
© Georg Thieme Verlag KG Stuttgart · New York

EFFICACY AND SAFETY OF ENDOSCOPIC SLEEVE GASTROPLASTY IN THE TREATMENT OF OVERWEIGHT AND OBESE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

AM Neto
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
IB Ribeiro
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
DTH de Moura
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
WM Bernardo
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
S Singh
2   Brigham and Women’s Hospital, Division of Gastroenterology, Hepatology and Endoscopy, Boston, United States of America
,
M Coronel
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
P Sakai
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
EGH de Moura
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
› Author Affiliations
Further Information

Publication History

Publication Date:
23 April 2020 (online)

Also available at
 

Aims Bariatric surgery is the most effective treatment for obesity and associated comorbidities; however, only 2% of eligible patients undergo surgery. Endoscopic Bariatric and Metabolic Therapies (EBMT) have recently gained popularity due to their minimally invasive nature and higher patient acceptability. Among the EBMTs, Endoscopic Sleeve Gastroplasty (ESG) is a promising procedure, and many recent studies have reported outcomes at short and medium-term follow-up. The aim of this study is to evaluate the efficacy and safety of ESG for the treatment of overweight and obese patients.

Methods This systematic review was conducted according to the PRISMA guidelines. Searches were performed on Medline (Pubmed), Cochrane Library, EMBASE, and LILACS databases without any language restrictions from their dates of inception to October 2019. Outcomes evaluated were: excess weight loss (%EWL), total weight loss (%TWL), absolute weight loss (AWL), and procedure-related adverse events.

Results Out of a total of 24,680 studies, 11 studies with a total of 2,170 patients met the inclusion criteria and were eligible for analysis. Eight included studies were prospective, and 3 were retrospective. The mean pre-procedure weight was 98.43 kg. The pooled mean %TWL at 6, 12 and 18 months was 15.32%, 16.15%, and 16.8%, respectively. Whereas the pooled mean %EWL at 6, 12 and 18 months was 55.80%, 60.07%, and 73.04%, respectively. The mean AWL at 6, 12 and 18 months was 14.88 kg, 17.32 kg, and 15.95 kg, respectively. The pooled incidence of severe adverse events (SAE) was 0,8% and there was no procedure-related mortality. Gastrointestinal bleeding and peri-gastric fluid collection were the most common reported SAE. Two patients required surgical intervention for the management of SAEs.

Conclusions ESG has demonstrated safety and efficacy in the short and medium-term, with a lower rate of adverse events and is a minimally invasive alternative promising in the treatment of obesity.